Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + apatinib + chemotherapy after progression or intolerance on first-line PD-1 therapy in NSCLC
ChiCTR2500099852Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab and Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoint: Progression-free survival. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500099852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099852.